Portfolio Designed for Impact

OpSens Medical announced its intent to be aquired by Haemonetics for $345 million in October 2023. The company is a pioneer of innovative fiber optic sensing technology offering more accurate diagnostic and treatment solutions for patients with coronary artery disease.

Industry: Medical Device | Headquarters: Quebec City, Quebec

Engage Therapeutics was acquired by UBC for up to US$270 million in June 2020, having developed the first on-demand rescue treatment for the rapid termination of active epileptic seizures.

Industry: Biopharmaceutical | Headquarters: Summit, New Jersey

Pharmasset was acquired by Gilead in 2011 for $11 billion, having developed the first oral therapeutic for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Industry: Biopharmaceutical | Headquarters: Princeton, New Jersey

MAKO Surgical developed a minimally invasive, more confident robotic surgical arm for partial knee and total hip arthroplasty and was acquired by Stryker for $1.65 billion in 2013.

Industry: Medical Device | Headquarters: Weston, Florida

Aurinia Pharmaceuticals has developed the first oral therapy for lupus nephritis, a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death.

Industry: Biotechnology | Headquarters: Edmonton, Alberta

Bardy was acquired by Hillrom for $375 million in January 2021, having developed and commercialized the most diagnostically-accurate and patient-friendly cardiac patch and monitoring solutions for patients with cardiovascular disease.

Industry: Medical Device | Headquarters: Seattle Washington

Zymeworks is developing best-in-class bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory disease.

Industry: Biotechnology | Headquarters: Vancouver, British Columbia

Spinal Kinetics was acquired by Orthofix in March 2018, having developed advanced artificial discs for degenerative diseases of the spine.

Industry: Medical Device | Headquarters: Sunnyvale, California

Developer of novel therapeutics for kidney disease, KAI Pharmaceuticals was acquired by Amgen in 2012 for US$315 million.

Industry: Biopharmaceutical | Headquarters: San Francisco, California

Ception Therapeutics was acquired by Cephalon Inc. in March 2010 for $350 million plus significant future millstones with its lead product which was subsequently approved to treat eosinophilic asthma.

Industry: Biopharmaceutical | Headquarters: Malvern, Pennsylvania

From the time we invested in 2002 to our exit in 2006, ISTA Pharmaceuticals launched 3 products in the United States to treat diseases of the eye.

Industry: Biopharmaceutical | Headquarters: Irvine, California

ESSA Pharmaceuticals is developing a small molecule therapy to overcome the issue of drug resistance and provide additional benefits for patients with prostate cancer.

Industry: Biotechnology | Headquarters: Vancouver, British Columbia

Forbius was acquired by Bristol Myers Squibb in August 2020, a company targeting hard-to-drug TFG-beta and EGFR pathways in Fibrosis and Cancer.

Industry: Biopharmaceutical | Headquarters: Montreal, Quebec

Corus Pharmaceuticals, developer of Aztreonam for the treatment of cystic fibrosis and Lidocaine for the treatment of oral corticosteroid-dependent asthma, was acquired by Gilead in August 2006 for $365 million.

Industry: Biopharmaceutical | Headquarters: Seattle, Washington

Morphotek was acquired by Eisai in April 2007 for $325 million, with a pipeline of treatments for oncology, inflammatory, and infectious diseases.

Industry: Biopharmaceutical | Headquarters: Exton, Pennsylvania

Alveolus, developer of next-generation non-vascular interventional stent technology for use in the lungs was acquired by Merit Medical Systems Inc. in February 2008.

Industry: Biotechnology | Headquarters: Boston, Massachusetts

Resonant Medical was acquired by Elekta in May 2010, having developed 3D ultrasound non-invasive and non-ionizing image-guided radiotherapy products for the treatment of cancer.

Industry: Medical Device | Headquarters: Montreal, Quebec

Lumira Ventures led a PIPE in Depomed in 2003 and fully exited in 2006 after the FDA approved the company’s two lead products in 2005 for treatment of pain and diseases of the central nervous system.

Industry: Biopharmaceutical | Headquarters: Newark, California

Guava Technologies was acquired by Millipore Inc. in February 2009, having developed and manufactured unique flow cytometry systems.

Industry: Biopharmaceutical | Headquarters: Hayward, California

Think Research develops knowledge-based and leading clinical content tools that empower clinicians to deliver the best evidence-based care to patients and drive greater patient outcomes.

Industry: Biopharmaceutical | Headquarters: Toronto, Ontario

U-Systems was acquired by GE Healthcare Limited in November 2012, having developed and commercialized a breakthrough ultrasound system for greater breast cancer detection.

Industry: Medical Device | Headquarters: Sunnyvale, California

Industry: Biotechnology | Headquarters: Toronto, Ontario

AmacaThera is developing a unique, injectable hydrogel platform technology to deliver localized therapeutics that are long-lasting and applicable to several indications.

Industry: Biopharmaceutical | Headquarters: Toronto, Ontario

Antiva Biosciences is developing first-in-class topical therapies aimed at treating the pre-cancerous lesions caused by HPV infection.

Industry: Biopharmaceutical | Headquarters: San Francisco, California

Arclight Therapeutics is building a pipeline of early-stage companies focused on the development of novel therapeutics for neurodegenerative diseases.

Industry: Biopharmaceutical | Headquarters: Cambridge, Massachusetts

BioTheryX is advancing a portfolio of first-in-class protein degraders to transform patient treatment across a wide range of inflammatory disorders and serious cancers.

Industry: Biopharmaceutical | Headquarters: San Diego, California

Tackling the problem of resistance to current antifungal therapies, Bright Angel Therapeutics is developing novel therapeutics to treat these life-threatening invasive fungal infections.

Industry: Biopharmaceutical | Headquarters: Toronto, Ontario

Cadence Neuroscience is developing a novel neuromodulation therapy with the potential to treat many neurological diseases that cannot be adequately addressed with available treatment options.

Industry: Medical Device | Headquarters: Redmond, Washington

Cardiac Dimensions is developing a minimally invasive implantable product to treat mitral valve regurgitation associated with congestive heart failure.

Industry: Medical Device | Headquarters: Kirkland, Washington

At the interface of computational and experimental drug discovery, Congruence Therapeutics is designing novel small molecules to treat diseases caused by protein misfolding.

Industry: Biopharmaceutical | Headquarters: Saint Laurent, Quebec City

Corvia Medical is developing a catheter-delivered implant to reduce symptoms and hospitalizations, while improving the treatment of heart failure with preserved ejection fraction (HFpEF).

Industry: Medical Device | Headquarters: Tewksbury, Massachusetts

COUR Pharmaceuticals is developing first-in-class therapies designed to achieve antigen-specific tolerance for immune-mediated disease. 

Industry: Biopharmaceutical | Headquarters: Skokie, Illinois

Cyrano Therapeutics is developing a novel therapy to restore chronic loss of taste and smell function in patients.

Industry: Biopharmaceutical | Headquarters: Washington, DC

DAMONA Pharmaceuticals is on a mission to develop small molecule therapeutics to improve the lives of patients suffering from cognitive impairment as a result of depression and other diseases of aging.

Industry: Biopharmaceutical | Headquarters: Toronto, Ontario

DEKA Biosciences is developing novel cytokine therapies to drive treatments for cancer patients and control inflammatory diseases.

Industry: Biopharmaceutical | Headquarters: Germantown, Maryland

Edesa Biotech is developing new treatments to help patients with limited options for inflammatory and immune-related diseases.

Industry: Biopharmaceutical | Headquarters: Markham, Ontario

Endogenex is shifting the treatment paradigm for people living with Type 2 Diabetes by resetting cellular signaling to help the body better manage blood sugar levels.

Industry: Biopharmaceutical | Headquarters: Plymouth, MN

Endotronix is developing an integrated platform to provide proactive, comprehensive health management tools for patients suffering from advanced heart failure.

Industry: Medical Device | Headquarters: Naperville, Illinois

enGene is developing a platform that has the potential to streamline the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues.

Industry: Biopharmaceutical | Headquarters: St Laurent, Quebec

Exact Imaging is the world’s leader in high-resolution systems enabling real-time imaging and guided biopsies for prostate cancer.

Industry: Medical Device | Headquarters: Markham, Ontario

Fusion Pharmaceuticals is developing next-generation radio-pharmaceuticals as precision medicines for the treatment of cancer.

Industry: Biopharmaceutical | Headquarters: Hamilton, Ontario

GenEp is developing first-in-class highly selective compounds that treat rare genetic and treatment-resistant epilepsies.

Industry: Biotechnology | Headquarters: Charlottesville, Virginia

G1 Therapeutics is focused on the development of small-molecule therapies to address high unmet needs in oncology including triple-negative breast cancer and extensive stage small cell lung cancer.

Industry: Biopharmaceutical | Headquarters: North Carolina

Histosonics is developing a non-invasive, image-guided method of tumor destruction for more effective cancer treatment, based on the science of histotripsy.

Industry: Medical Device | Headquarters: Plymouth, MN

IMV is developing a novel suite of immunotherapeutics producing a more rapid, robust, and sustained immune response to target and treat specific diseases with unmet clinical needs.

Industry: Biopharmaceutical | Headquarters: Dartmouth, Nova Scotia

Iterion Therapeutic is developing novel cancer therapeutics targeting nuclear β-catenin, a historically “undruggable” oncology target implicated in cell proliferation.

Industry: Biopharmaceutical | Headquarters: Houston, Texas

Kalgene is focused on the development of precision medicine therapeutics to slow the progression of Alzheimer’s disease.

Industry: Biopharmaceutical | Headquarters: Candiac, Quebec

Kisoji is developing leading next-generation multi-specific antibodies to address difficult targets in oncology and other diseases.

Industry: Biotechnology | Headquarters: Toronto, Ontario

Medexus Pharmaceuticals is developing a best-in-class portfolio of innovative and high-valued orphan treatments for rare disease.

Industry: Biopharmaceutical | Headquarters: Bolton, Ontario

Nocion Therapeutics is developing novel small molecule CSCBs, “nocions,” that selectively affect actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain

Industry: Biotechnology | Headquarters: Watertown, Massachusetts

Notch Therapeutics is developing a next-generation pipeline of genetically tailored T-cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.

Industry: Biotechnology | Headquarters: Vancouver, British Columbia

PIC Therapeutics is developing a new generation of therapeutics based on the modulation of RNA translation to improve how cancer is treated.

Industry: Biotechnology | Headquarters: Natick, Massachusetts

Specific Biologics is developing a next generation gene-editing platform to accurately edit cells in a target tissue to treat certain genetic diseases.

Industry: Biopharmaceutical | Headquarters: Toronto, Ontario

Thryv Therapeutics is pioneering a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias.

Industry: Biopharmaceutical | Headquarters: Montreal, Quebec

Transposon Therapeutics specializes in the development of genetic therapeutics for the treatment of neurodegenerative diseases.

Industry: Biopharmaceutical | Headquarters: Westport, Connecticut

X4 Pharmaceuticals a leader in the discovery and development of novel therapies for the treatment of immune system diseases.

Industry: Biopharmaceutical | Headquarters: Boston, Massachusetts

XyloCor Therapeutics is developing a novel gene therapy for unmet needs in advanced coronary artery disease.

Industry: Biotechnology | Headquarters: Wayne, PA